Harvard Bioscience will distribute the IonFlux and BioFlux Systems, targeting the electrophysiology and live cell imaging markets
SAN FRANCISCO, Nov. 14, 2017 /PRNewswire/ — Fluxion Biosciences, a leading developer of automated solutions for cellular analysis in life sciences research and drug discovery, today announced that it has signed a distribution agreement with Harvard Biosciences. The distribution agreement covers Fluxion’s BioFlux™ and IonFlux™ platforms for sale to Harvard Bioscience’s customers in North America.
Fluxion’s BioFlux system is used by leading researchers for automated, high throughput studies of cell-cell interactions, and complements Harvard Bio’s existing perfusion systems. The IonFlux system is used by leading pharmaceutical companies and academic labs for ion channel research and drug discovery. IonFlux utilizes a “plate reader” format for simple user operation, yet provides the flexibility to run highly complex assays for applications such as ligand-gated ion channels. IonFlux is a natural addition to Harvard Bio’s broad portfolio of electrophysiology products.
“Harvard Bioscience is an ideal partner to distribute the IonFlux and BioFlux systems. They have developed a well-deserved reputation for delivering top-quality products and services to the electrophysiology market,” stated Jeff Jensen, CEO of Fluxion.
“We are delighted to distribute Fluxion’s IonFlux and BioFlux Systems,” said John Battista, North American Sales Director for Electrophysiology Products at Harvard Bioscience. “IonFlux is a perfect fit with our other electrophysiology products, and extends our capabilities to high throughput automated analysis. We can now serve the full range of needs of our electrophysiology customers, from gold-standard, single cell manual patch clamp to ion channel screening, pharmacology and toxicology applications. Similarly, the BioFlux System is a natural extension of our well-established Warner Instruments flow cell portfolio, permitting higher-throughput, microfluidic processing of eukaryotic and bacterial assays under flow.”
About Fluxion Biosciences
Fluxion Biosciences is a global leader in delivering bench-top solutions for predictive discovery and precision diagnostics. Products include the BioFlux System for cellular interaction assays, the IonFlux Automated Patch Clamp System, IsoFlux Circulating Tumor Cell System, and ERASE-Seq liquid biopsy sequencing technology. For more information about Fluxion Biosciences, visit www.fluxionbio.com.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors. For more information, please visit our website at www.harvardbioscience.com.
Jeff Jensen, CEO
SOURCE Fluxion Biosciences